SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-015041
Filing Date
2023-05-01
Accepted
2023-05-01 17:26:18
Documents
15
Period of Report
2023-04-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 50729
2 ex1-1.htm EX-1.1 287667
3 ex5-1.htm EX-5.1 13010
4 ex5-1_001.jpg GRAPHIC 22202
  Complete submission text file 0001493152-23-015041.txt   621278

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE sava-20230426.xsd EX-101.SCH 3248
6 XBRL LABEL FILE sava-20230426_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE sava-20230426_pre.xml EX-101.PRE 22373
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3621
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

IRS No.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-29959 | Film No.: 23875335
SIC: 2834 Pharmaceutical Preparations